121 related articles for article (PubMed ID: 2195616)
1. Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study.
Los G; Nagel JD; McVie JG
Sel Cancer Ther; 1990; 6(2):73-82. PubMed ID: 2195616
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Keese M; Gasimova L; Schwenke K; Yagublu V; Shang E; Faissner R; Lewis A; Samel S; Löhr M
Int J Cancer; 2009 Jun; 124(11):2701-8. PubMed ID: 19165866
[TBL] [Abstract][Full Text] [Related]
3. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal tumor growth and chemotherapy in a rat model.
Los G; Ruevekamp M; Bosnie N; De Graaf PW; McVie JG
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1857-66. PubMed ID: 2632267
[TBL] [Abstract][Full Text] [Related]
5. Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads.
Yagublu V; Caliskan N; Lewis AL; Jesenofsky R; Gasimova L; Löhr JM; Keese M
Pancreatology; 2013; 13(1):79-87. PubMed ID: 23395574
[TBL] [Abstract][Full Text] [Related]
6. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
Hribaschek A; Meyer F; Schneider-Stock R; Pross M; Ridwelski K; Lippert H
Chemotherapy; 2007; 53(6):410-7. PubMed ID: 17952000
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin for chemotherapeutic treatment and prevention of experimental peritoneal carcinomatosis in rats comparing the intraperitoneal and intravenous application mode.
Hribaschek A; Meyer F; Ridwelski K; Kuester D; Lippert H
Eur Surg Res; 2010; 44(2):74-81. PubMed ID: 20051689
[TBL] [Abstract][Full Text] [Related]
9. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
10. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules.
Yamashita K; Tsunoda S; Gunji S; Murakami T; Suzuki T; Tabata Y; Sakai Y
Surg Today; 2019 Sep; 49(9):785-794. PubMed ID: 30847629
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
13. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.
Nowacki M; Alyami M; Villeneuve L; Mercier F; Hubner M; Willaert W; Ceelen W; Reymond M; Pezet D; Arvieux C; Khomyakov V; Lay L; Gianni S; Zegarski W; Bakrin N; Glehen O
Eur J Surg Oncol; 2018 Jul; 44(7):991-996. PubMed ID: 29526367
[TBL] [Abstract][Full Text] [Related]
14. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
Tempfer CB; Giger-Pabst U; Seebacher V; Petersen M; Dogan A; Rezniczek GA
Gynecol Oncol; 2018 Jul; 150(1):23-30. PubMed ID: 29743140
[TBL] [Abstract][Full Text] [Related]
15. [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Hribaschek A; Pross M; Ridwelski K; Meyer F; Fenske A; Krüger S; Lippert H
Zentralbl Chir; 2004 Aug; 129(4):328-34. PubMed ID: 15354258
[TBL] [Abstract][Full Text] [Related]
16. Intracavitary chemotherapy.
Markman M
Curr Probl Cancer; 1986 Aug; 10(8):401-37. PubMed ID: 2427278
[No Abstract] [Full Text] [Related]
17. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.
Esquis P; Consolo D; Magnin G; Pointaire P; Moretto P; Ynsa MD; Beltramo JL; Drogoul C; Simonet M; Benoit L; Rat P; Chauffert B
Ann Surg; 2006 Jul; 244(1):106-12. PubMed ID: 16794395
[TBL] [Abstract][Full Text] [Related]
18. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
Bregman CL; Williams PD
Cancer Chemother Pharmacol; 1986; 18(2):117-23. PubMed ID: 3539384
[TBL] [Abstract][Full Text] [Related]
19. The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administration.
Tinker N; De Spiegeleer B; Sharma H; Jackson H; McAuliffe C; Reman JP
Int J Rad Appl Instrum B; 1990; 17(4):427-36. PubMed ID: 2201668
[TBL] [Abstract][Full Text] [Related]
20. [Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats].
Chauffert B; Dimanche-Boitrel MT; Genne P; Petit JM; Onier N; Jeannin JF
Gastroenterol Clin Biol; 1992; 16(3):215-9. PubMed ID: 1582536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
